Amgen’s incomplete report on an early major trial of epoetin misled the medical community about the anemia drug’s risks and benefits—and helped make Amgen rich.
Covering the life sciences inside and out
Amgen’s incomplete report on an early major trial of epoetin misled the medical community about the anemia drug’s risks and benefits—and helped make Amgen rich.
By discouraging change, universities are stunting scientific innovation, leadership, and growth.
Researchers identify two new DNA repair systems, in addition to four that were already known, that can attack unprotected telomeres.
A lack of methodological detail in the published literature threatens the foundation of scientific discourse.
A US Fish and Wildlife official responds to the assertion that the northern spotted owl is being mismanaged by government.
From breast milk stem cells to bone repair, this year’s EB conference held a number of exciting advances that could one day be translated into therapies.
With 12 new tuberculosis vaccines in clinical development, a plan is needed to introduce the most effective ones throughout the world.
Introducing DELSA Global, a community initiative to connect experts, share data, and democratize science.
The pitfalls of using public meetings as surrogate gauges of public opinion
A roundup of recent research announced this week at the annual conference of the American Association for Cancer Research (AACR).